REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association Conference

The biotech company will share preclinical and clinical data on its investigational gene therapy for Duchenne muscular dystrophy.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

REGENXBIO Inc., a biotechnology company focused on gene therapy, announced that it will present data on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida. The presentations will include preclinical and Phase I/II clinical safety, biomarker, and functional data.

Why it matters

REGENXBIO's RGX-202 is a potential one-time treatment for Duchenne muscular dystrophy, a rare and devastating genetic disorder that causes progressive muscle degeneration and weakness. The company's presentations at the MDA conference will provide important updates on the development of this investigational gene therapy, which could offer hope for patients and families affected by this debilitating disease.

The details

The presentations will include a podium presentation on the interim Phase I/II clinical data for RGX-202, as well as a poster presentation on preclinical research showing that the microdystrophin protein used in RGX-202 can protect against cardiac damage and remodeling in an animal model of Duchenne. REGENXBIO will also host a symposium at the conference titled "Advancing Duchenne Gene Therapy Trials in a New Era: Optimizing Design and Interpretation".

  • The 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference will take place in Orlando, Florida from March 8-11, 2026.
  • The podium presentation on RGX-202 interim Phase I/II data will be held on March 11, 2026 at 11:45 a.m. ET.
  • The poster presentation on preclinical research will be presented during the Pre-Clinical Research session.
  • The REGENXBIO symposium will take place on March 9, 2026 at 12 p.m. ET.

The players

REGENXBIO Inc.

A biotechnology company focused on developing gene therapies, including the investigational RGX-202 treatment for Duchenne muscular dystrophy.

Carolina Tesi Rocha, M.D.

Clinical Professor of Neurology at Stanford School of Medicine and Stanford Children's Health, who will present the interim Phase I/II clinical data for RGX-202.

Steven Foltz, Ph.D.

Principal Scientist, Gene Therapy Research at REGENXBIO, who will present the preclinical research poster on the microdystrophin protein used in RGX-202.

Got photos? Submit your photos here. ›

The takeaway

REGENXBIO's presentations at the MDA conference highlight the company's progress in developing a potential one-time gene therapy treatment for Duchenne muscular dystrophy, a devastating disease with limited treatment options. The data shared will be closely watched as the field of gene therapy continues to advance.